T2 Biosystems Reports 2014 Fourth Quarter, Full Year Results

LEXINGTON, Mass., Feb. 17, 2015 (GLOBE NEWSWIRE) -- T2 Biosystems (Nasdaq:TTOO) today reported operating highlights and financial results for the fourth quarter and year ended December 31, 2014. Recent operational highlights included:

  • This month, the Company entered into a multi-year, strategic agreement with Canon U.S. Life Sciences, Inc. to jointly develop a novel diagnostic test to rapidly detect Lyme disease
  • In January, results from the first large, multi-center clinical trial for the T2Candida® Panel and the T2Dx® Instrument were published in Clinical Infectious Disease and demonstrated 91.1% sensitivity and specificity of 99.4% for sepsis pathogen detection in 3-5 hours without the need for blood culture
  • In January, an article supporting the use of T2MR® as a platform with the potential to significantly impact the field of diagnostics was published in The Journal of the American Medical Association (JAMA)
  • In October, T2Candida and T2Dx were included in four oral and poster presentations during IDWeek 2014™.

President and CEO John McDonough said, "The pace of commercial and operational progress and activity at T2 Biosystems accelerated as we closed out 2014 and entered the new year. Key clinical publications are providing even greater opportunities and evidence for our expanding sales organization to engage with target facilities throughout the US and we are very encouraged by those initial interactions and the number of institutions that are now in various stages of the adoption process."

Financial Results

Through the fourth quarter, the Company has generated revenue primarily from research and development agreements and government grants and has not generated any revenue from the sale of products. In the 2014 fourth quarter and full year, T2 Biosystems recorded $119,000 of research and grant revenue for both periods, compared to $55,000 and $266,000 in the prior year periods. These amounts primarily consisted of revenue related to feasibility studies and co-development efforts with third parties.

Total operating expenses for the 2014 fourth quarter and full year were $9.0 million and $30.8 million, respectively, compared to $5.7 million and $20.0 million for the 2013 periods. The increases in operating expenses for the year were mainly associated with the direcT2 pivotal clinical trial and other regulatory support and activity, research and development activities for additional applications of T2MR, expansion of marketing programs, build-out of the US commercial infrastructure, and increases in share-based compensation charges and incremental expenses related to being a public company.

The net loss applicable to common shareholders for the 2014 fourth quarter was $9.1 million, or $0.45 loss per share, compared to $8.3 million (after adjustments for accretion of redeemable convertible preferred stock), or $5.89 loss per share for the 2013 fourth quarter. The increased loss was principally due to increased operating expenses noted above. For 2014, the net loss applicable to common shareholders was $36 million, or $4.15 loss per share, compared to $27.5 million, or $19.72 loss per share for 2013. Loss per share calculations for each of the periods reported were impacted by the overall increase in common shares outstanding resulting from the August 7, 2014 initial public offering (IPO).

The Company's balance sheet as of December 31, 2014, showed total cash and cash equivalents of $73.8 million.

Conference Call

T2 Biosystems' management will discuss the Company's financial results for the fourth quarter and year ended December 31, 2014, and provide a general business update during a conference call beginning at 4:30 p.m. Eastern Standard Time today, Tuesday, February 17, 2015. To join the call, participants may dial 1-877-407-4018 (U.S.) or 1-201-689-8471 (International). To listen to the live call via T2 Biosystems' website, go to www.t2biosystems.com, in the Events & Presentations section. A webcast replay of the call will be available for 30 days following the conclusion of the call in the Events & Presentations section of the website.

About T2 Biosystems

T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the performance of the Company's diagnostic products and the ability to bring such products to market. These and other important factors discussed under the caption "Risk Factors" in the Company's final prospectus filed with the Securities and Exchange Commission, pursuant to Rule 424(b) of the Securities Act of 1933, as amended, on August 7, 2014, and in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2014, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.

– Tables to Follow –

T2 Biosystems, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
Three Months Ended
December 31,
Twelve Months Ended
December 31,
2014 2013 2014 2013
Research and grant revenue $ 119 $ 55 $ 119 $ 266
Operating expenses:
Research and development expenses 5,210 4,290 19,782 14,936
Selling, general and administrative expenses 3,747 1,404 11,018 5,022
Total operating expenses 8,957 5,694 30,800 19,958
Loss from operations (8,838) (5,639) (30,681) (19,692)
Interest expense, net (251) (93) (721) (403)
Other income (expense), net 13 (642) 12 (515)
Net loss $ (9,076) $ (6,374) $ (31,390) $ (20,610)
Comprehensive loss $ (9,076) $ (6,374) $ (31,390) $ (20,610)
Reconciliation of net loss to net loss applicable to common stockholders:
Net loss $ (9,076) $ (6,374) $ (31,390) $ (20,610)
Accretion of redeemable convertible preferred stock to redemption value -- (1,910) (4,570) (6,908)
Net loss applicable to common stockholders $ (9,076) $ (8,284) $ (35,960) $ (27,518)
Net loss per share applicable to common stockholders - basic and diluted $ (0.45) $ (5.89) $ (4.15) $ (19.72)
Weighted-average number of common shares used in computing net loss per share applicable to common stockholders - basic and diluted 20,041,577 1,405,607 8,674,931 1,395,562
T2 Biosystems, Inc.
Condensed Balance Sheets
(In thousands, except share and per share data)
December 31,
December 31,
Current Assets:
Cash and cash equivalents $ 73,849 $ 30,198
Accounts receivable 201 --
Prepaid expenses and other current assets 1,156 195
Inventory 115 --
Total current assets 75,321 30,393
Property and equipment, net 2,760 1,118
Restricted cash 260 340
Other assets 480 34
Total assets $ 78,821 $ 31,885
Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)
Current liabilities:
Accounts payable $ 735 $ 943
Accrued expenses and other current liabilities 3,662 1,319
Current portion of notes payable 295 1,759
Current portion of deferred rent 87 25
Deferred revenue 80 --
Total current liabilities 4,859 4,046
Notes payable, net of current portion 20,660 3,299
Deferred rent, net of current portion 106 45
Warrants to purchase redeemable securities -- 1,225
Other liabilities 195 --
Commitments and contingencies
Redeemable convertible preferred stock -- 112,813
Stockholders' equity (deficit):
Common stock, $0.001 par value; 200,000,000 and 28,254,907 shares authorized at December 31, 2014 and 2013, respectively; 20,041,645 and 1,411,986 shares issued and outstanding at December 31, 2014 and 2013, respectively 20 1
Additional paid-in capital 156,576 --
Accumulated deficit (103,595) (89,544)
Total stockholders' equity (deficit) 53,001 (89,543)
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) $ 78,821 $ 31,885

CONTACT: Media Contact: Dan Budwick, Pure Communications dan@purecommunicationsinc.com 973-271-6085 Investor Contact: Matt Clawson, Pure Communications matt@purecommunicationsinc.com 949-370-8500

Source:T2 Biosystems, Inc.